title: Liver mitochondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging rats.
abstract: BACKGROUND
  Serum IGF-I and IGF-II levels decline with age. IGF-I replacement therapy reduces the impact of age in rats. We have recently reported that IGF-II is able to act, in part, as an analogous of IGF-I in aging rats reducing oxidative damage in brain and liver associated with a normalization of antioxidant enzyme activities. Since mitochondria seem to be the most important cellular target of IGF-I, the aim of this work was to investigate whether the cytoprotective actions of IGF-II therapy are mediated by mitochondrial protection.
  
  
  METHODS
  Three groups of rats were included in the experimental protocol young controls (17 weeks old); untreated old rats (103 weeks old); and aging rats (103 weeks old) treated with IGF-II (2 μg/100 g body weight and day) for 30 days.
  
  
  RESULTS
  Compared with young controls, untreated old rats showed an increase of oxidative damage in isolated mitochondria with a dysfunction characterized by: reduction of mitochondrial membrane potential (MMP) and ATP synthesis and increase of intramitochondrial free radicals production and proton leak rates. In addition, in untreated old rats mitochondrial respiration was not blocked by atractyloside. In accordance, old rats showed an overexpression of the active fragment of caspases 3 and 9 in liver homogenates. IGF-II therapy corrected all of these parameters of mitochondrial dysfunction and reduced activation of caspases.
  
  
  CONCLUSIONS
  The cytoprotective effects of IGF-II are related to mitochondrial protection leading to increased ATP production reducing free radical generation, oxidative damage and apoptosis.
authors.affiliation: Department of Physiology, School of Medicine, University of Málaga, 29071 Málaga, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Garcia-Fernandez
authors.forename: Inma
authors.initials: I
authors.lastname: Sierra
authors.forename: Juan E
authors.initials: JE
authors.lastname: Puche
authors.forename: Lucia
authors.initials: L
authors.lastname: Guerra
authors.forename: Inma
authors.initials: I
authors.lastname: Castilla-Cortazar
mesh_terms: D025181:ATP Synthetase Complexes / Q000378:metabolism; D000375:Aging / Q000187:drug effects* / Q000378:metabolism*; D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001278:Atractyloside / Q000494:pharmacology; D053148:Caspase 3 / Q000378:metabolism; D053453:Caspase 9; D003576:Electron Transport Complex IV / Q000378:metabolism; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D011522:Protons; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000975:Antioxidants; D011522:Protons; D001278:Atractyloside; D007335:Insulin-Like Growth Factor II; D006861:Hydrogen Peroxide; D003576:Electron Transport Complex IV; D025181:ATP Synthetase Complexes; D053148:Caspase 3; D053453:Caspase 9